bluebird bio Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
25,321.00
48,709.00
166,783.00
263,507.00
335,643.00
555,625
Depreciation, Depletion & Amortization
941.00
4,228.00
7,419.00
9,648.00
13,538.00
17,158
Other Funds
344.00
-
453.00
362.00
1,074.00
105,801
Funds from Operations
17,440.00
44,959.00
114,387.00
208,603.00
267,859.00
432,666
Changes in Working Capital
60,890.00
14,734.00
15,958.00
18,956.00
12,694.00
19,240
Net Operating Cash Flow
43,450.00
59,693.00
98,429.00
189,647.00
280,553.00
413,426
Capital Expenditures
8,670.00
8,708.00
7,055.00
28,029.00
62,242.00
Purchase/Sale of Investments
-
144,021.00
564,812.00
90,760.00
253,761.00
Net Investing Cash Flow
9,823.00
157,193.00
571,867.00
62,731.00
316,003.00
Issuance/Reduction of Debt, Net
-
-
-
-
37,447.00
Net Financing Cash Flow
105,641.00
358,452.00
486,720.00
241,534.00
1,076,174.00
Net Change in Cash
139,268.00
141,566.00
183,576.00
114,618.00
479,618.00
Free Cash Flow
34,780.00
68,401.00
105,484.00
217,676.00
342,795.00
Net Assets from Acquisitions
-
4,673.00
-
-
-
Other Sources
-
209.00
-
-
-
Change in Capital Stock
105,297.00
358,452.00
487,173.00
241,896.00
1,039,801.00
Other Uses
1,153.00
-
-
-
-

About bluebird bio

View Profile
Address
60 Binney Street
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.bluebirdbio.com
Updated 07/08/2019
bluebird bio, Inc. is a clinical-stage biotechnology company. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. It offers the LentiGlobin which is a treatment for transfusion-dependent ß-thalassemia; and Lenti-D as a treatment for cerebral adrenoleukodystrophy.